Precision NanoSystems’ Genetic Medicine Toolkit comprises proprietary lipid nanoparticle and microfluidic manufacturing platforms supported by comprehensive expertise to enable researchers to translate disease biology insights into non-viral genetic medicines.
Workflows use the Genetic Medicine Toolkit for the rapid and cost-effective development of non-viral based vaccines, cell therapies and gene therapies. These therapeutic modalities have broad application in the prevention and treatment of diseases including infectious disease, rare disease and cancer.
Use the NanoAssemblr Manufacturing platform and the GenVoy Delivery platform from the Genetic Medicine Toolkit in your laboratories. Our global team is available for onsite support.
Precision has an experienced team dedicated to development of genetic medicines on behalf of our partners. Our team uses the Genetic Medicine Toolkit and Workflows to develop vaccines, gene therapies and cell therapies from idea to commercial product.
The scalability and reproducibility of PNI’s NanoAssemblr platform allowed us to move into GMP manufacturing with greater control over the process and increased precision in the final product compared to our previous macromixing process, allowing acceleration of our time to commercialization.
Chief Scientific Officer
Our government is bringing back the vaccine manufacturing capacity that Canadians expect and need. These investments will help to ensure that Canada has modern, flexible vaccine manufacturing capabilities now and in the future. With the investments announced today, our government is helping Canadian...Read More
Minister of Innovation, Science and Industry
Government of Canada
The ease, reproducibility, and the robustness of PNI’s products is amazing compared to what we previously had used, and that’s been a real enabling factor for Guide as we’ve continued to grow over the last year and a half.
Chief Technology Officer
As an Evonik affiliate specialized in liposomal drug delivery systems, we are pleased to offer our clients access to the NanoAssemblr GMP System, which will aid in the translation of drug candidates to clinical testing and ideally to commercial use.
Evonik Vancouver Laboratories
Ajinomoto Bio-Pharma Services has audited the PNI facilities in Vancouver and has qualified PNI's NanoAssemblr GMP System and its components. We are excited to work with PNI to offer their purpose-designed manufacturing technology and unique nanomedicine expertise to our clients for the manufacture ...Read More
Vice President and Head of US Operations
Ajinomoto Bio-Pharma Services
We look forward to working with Precision NanoSystems to support research efforts around the discovery of novel sLNPs that we believe have the potential to significantly improve and broaden biodistribution. sLNPs represent an exciting and innovative approach in Alnylam’s advancement of proprietary L...Read More
Chief Scientific Officer
eTheRNA used the NanoAssemblr® NxGen technology because we could perform precise tuning of the size of our nanoparticles to target the optimal immunogenicity in vivo.
Vice President of Manufacturing
We are excited about this promising collaboration and hope that it will propel our work forward as the ncRNA Core Facility focuses on the non-coding RNA portions of the genome for [the] discovery of novel biomarkers and targets for therapeutics from human disease tissue and clinical trial specimens.
Director of Initiative for RNA
Harvard Medical School
Of particular note is LM03PE which had IgG levels of almost 108 ng/mL. We've never seen antibody levels this high.
Comments on PNI's proprietary RNA-LNP formulations eliciting a strong immune response in an influenza challenge study
Marie Skłodowska-Curie Research Fellow
Imperial College London